PM1022 is a bispecific that targets PD-L1 and TIGIT simultaneously. Preclinical studies have shown that Fc function potentiates the therapeutic activity of anitbodies that target TIGIT and PD-L1. PM1022 not only blocks PD-L1 and TIGIT binding to their interaction partners, but effector Fc function allows for killing towards PD-L1-positive tumor cells and TIGIT-postive Tregs.